Prevention Study in Adult Patients Suffering From Migraine Headaches

PHASE2CompletedINTERVENTIONAL
Enrollment

526

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Migraine DisordersMigraine
Interventions
DRUG

GSK1838262

Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day

DRUG

Placebo

Placebo-control

Trial Locations (59)

12206

GSK Investigational Site, Albany

15236

GSK Investigational Site, Pittsburgh

19107

GSK Investigational Site, Philadelphia

19139

GSK Investigational Site, Philadelphia

22311

GSK Investigational Site, Alexandria

27405

GSK Investigational Site, Greensboro

27607

GSK Investigational Site, Raleigh

27609

GSK Investigational Site, Raleigh

29412

GSK Investigational Site, Charleston

30281

GSK Investigational Site, Stockbridge

30308

GSK Investigational Site, Atlanta

32720

GSK Investigational Site, DeLand

33351

GSK Investigational Site, Sunrise

33407

GSK Investigational Site, West Palm Beach

35233

GSK Investigational Site, Birmingham

37203

GSK Investigational Site, Nashville

38018

GSK Investigational Site, Memphis

43081

GSK Investigational Site, Westerville

44195

GSK Investigational Site, Cleveland

45069

GSK Investigational Site, West Chester

49009

GSK Investigational Site, Kalamazoo

55422

GSK Investigational Site, Golden Valley

60642

GSK Investigational Site, Chicago

63141

GSK Investigational Site, St Louis

64111

GSK Investigational Site, Kansas City

65807

GSK Investigational Site, Springfield

67207

GSK Investigational Site, Wichita

77004

GSK Investigational Site, Houston

78205

GSK Investigational Site, San Antonio

80239

GSK Investigational Site, Denver

80904

GSK Investigational Site, Colorado Springs

80909

GSK Investigational Site, Colorado Springs

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

85016

GSK Investigational Site, Phoenix

85023

GSK Investigational Site, Phoenix

89119

GSK Investigational Site, Las Vegas

90404

GSK Investigational Site, Santa Monica

91361

GSK Investigational Site, Westlake Village

92374

GSK Investigational Site, Redlands

92660

GSK Investigational Site, Newport Beach

92801

GSK Investigational Site, Anaheim

94109

GSK Investigational Site, San Francisco

98195

GSK Investigational Site, Seattle

98801

GSK Investigational Site, Wenatchee

V2A 5C8

GSK Investigational Site, Penticton

V4H 2H9

GSK Investigational Site, Surrey

A0A 1G0

GSK Investigational Site, Bay Roberts

L6T 3T1

GSK Investigational Site, Brampton

P3E 1H5

GSK Investigational Site, Greater Sudbury

K1H 1A2

GSK Investigational Site, Ottawa

K2G 6E2

GSK Investigational Site, Ottawa

M3H 5S4

GSK Investigational Site, Toronto

M4S 1Y2

GSK Investigational Site, Toronto

M9W 4L6

GSK Investigational Site, Toronto

H2W 1V1

GSK Investigational Site, Montreal

G1S 2L6

GSK Investigational Site, Québec

G6W 5M6

GSK Investigational Site, Saint Romuald

J1H 4J6

GSK Investigational Site, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

XenoPort, Inc.

INDUSTRY

NCT00742209 - Prevention Study in Adult Patients Suffering From Migraine Headaches | Biotech Hunter | Biotech Hunter